Abstract Number: 1288 • 2019 ACR/ARP Annual Meeting
Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice
Background/Purpose: To evaluate the real-world accuracy of a line blot immunoassay (LIA) for myositis-specific (MSA) and myositis-associated (MSA) autoantibody testing in patients at a tertiary…Abstract Number: 1289 • 2019 ACR/ARP Annual Meeting
Antigen Bead Array versus ELISA to Detect anti-cN1A Antibodies in Patients with Sporadic Inclusion Body Myositis and Correlation with Clinical, Serological and Histological Features
Background/Purpose: Antibodies to cytosolic 5’-Nucleotidase 1A (anti-cN1A or NT5C1A) are considered the only currently known serum biomarker for sporadic Inclusion Body Myositis (sIBM). They are…Abstract Number: 1290 • 2019 ACR/ARP Annual Meeting
Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy
Background/Purpose: Activation of the type 1 interferon (IFN1) pathway is a prominent feature of dermatomyositis (DM) muscle and may play a role in the pathogenesis…Abstract Number: 1291 • 2019 ACR/ARP Annual Meeting
Semi-Quantitative and Quantitative Evaluation of Magnetic Resonance Imaging in Patients with Idiopathic Inflammatory Myopathies – a Subanalysis of the Prometheus Study
Background/Purpose: Prometheus study was a prospective, randomized, assessor-blind multicenter trial, comparing the efficacy and safety of the glucocorticoid (GC) monotherapy versus combination therapy with methotrexate…Abstract Number: 1292 • 2019 ACR/ARP Annual Meeting
Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies
Background/Purpose: Vascular inflammation and damage are implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM), particularly dermatomyositis (DM). High and low density lipoprotein (HDL, LDL)…Abstract Number: 1293 • 2019 ACR/ARP Annual Meeting
Multiple Subpopulations of Lymphocytes Were Absolutely Decreased in Dermatomyositis/polymyositis Patients and Restored by Low-dose IL-2
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare chronicinflammatory disorders with significant associated morbidityand mortality despite treatment, characterized by subacute onset of proximal muscle weakness,…Abstract Number: 1294 • 2019 ACR/ARP Annual Meeting
Alterations in Activin A-Myostatin-Follistatin System Associate with Disease Activity in Inflammatory Myopathies
Background/Purpose: The aim of this study was to investigate myokines involved in muscle atrophy such as myostatin, follistatin and activin A, in idiopathic inflammatory myopathies…Abstract Number: 1295 • 2019 ACR/ARP Annual Meeting
Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory myopathy in which the immunoregulatory control is not well understood. Collaboration with A.R. French, MD/PhD, documented the…Abstract Number: 1296 • 2019 ACR/ARP Annual Meeting
Increased MxA Protein Expression and Dendritic Cells in Spongiotic Dermatitis Differentiates Dermatomyositis from Eczema
Background/Purpose: Dermatomyositis (DM) is conventionally characterized by interface dermatitis (ID) on skin histopathology. A subset of patients with clinically diagnosed DM have skin biopsies showing…Abstract Number: 1297 • 2019 ACR/ARP Annual Meeting
Increased Hsp90 in Plasma and Muscle Tissue Associates with Disease Activity and Skeletal Muscle Involvement in Idiopathic Inflammatory Myopathies
Background/Purpose: Heat shock proteins (Hsps) are chaperones playing important roles in skeletal muscle physiology, adaptation to exercise or stress, and activation of inflammatory cells.The aim…Abstract Number: 1298 • 2019 ACR/ARP Annual Meeting
A Randomised Clinical Trial of Curcuma Longa Extract for Treating Symptoms and Effusion-Synovitis of Knee Osteoarthritis
Background/Purpose: Pharmacological therapies are limited, associated with off-target effects, are frequently contraindicated, and only modestly effective for pain in osteoarthritis (OA). Effusion and synovitis are…Abstract Number: 1299 • 2019 ACR/ARP Annual Meeting
Clinical Significance of Magnetic Resonance Imaging Derived Femur Bone Shape in Young Adults
Background/Purpose: The femur bone shape derived from magnetic resonance imaging (MRI) of the knee is associated with the incidence and progression of knee osteoarthritis (OA),…Abstract Number: 1300 • 2019 ACR/ARP Annual Meeting
Predictor of Placebo Response in Hand Osteoarthritis: A Post Hoc Analysis of Two Randomized Controlled Trials
Background/Purpose: Osteoarthritis (OA) in hands is common in middle-aged and elderly population. The mainstay treatment of hand OA is to control the symptoms with a combination of non-pharmacological and…Abstract Number: 1301 • 2019 ACR/ARP Annual Meeting
Rates of Incident Radiographic Knee Osteoarthritis and Knee Replacement by Sex and Race, Across Three Large, Diverse Cohorts
Background/Purpose: Previous studies have suggested differences in the development of incident radiographic knee osteoarthritis (RKOA) and the receipt of knee replacement (KR) by sex and…Abstract Number: 1302 • 2019 ACR/ARP Annual Meeting
Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
Background/Purpose: Tanezumab is a monoclonal antibody that inhibits nerve growth factor and is under investigation for chronic pain treatment. Tanezumab administered intravenously was effective and…
ACR Meeting Abstracts